IRIS Institutional Research Information System - OPENBS Open Archive UniBS

REGOLA, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.093
AS - Asia 684
EU - Europa 472
SA - Sud America 128
Continente sconosciuto - Info sul continente non disponibili 25
OC - Oceania 24
AF - Africa 19
Totale 2.445
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.038
SG - Singapore 264
CN - Cina 168
IT - Italia 130
DE - Germania 100
BR - Brasile 98
HK - Hong Kong 89
VN - Vietnam 59
FI - Finlandia 43
GB - Regno Unito 35
FR - Francia 29
UA - Ucraina 27
RU - Federazione Russa 25
AU - Australia 23
CA - Canada 20
BD - Bangladesh 18
IN - India 16
TR - Turchia 16
IE - Irlanda 15
NL - Olanda 13
SE - Svezia 11
AR - Argentina 10
JP - Giappone 10
MX - Messico 10
GR - Grecia 9
IQ - Iraq 8
PK - Pakistan 8
EG - Egitto 7
MK - Macedonia 7
CO - Colombia 6
CR - Costa Rica 6
AT - Austria 5
ES - Italia 5
PL - Polonia 5
SV - El Salvador 5
PH - Filippine 4
PR - Porto Rico 4
SA - Arabia Saudita 4
TH - Thailandia 4
TN - Tunisia 4
VE - Venezuela 4
CH - Svizzera 3
EC - Ecuador 3
HN - Honduras 3
JO - Giordania 3
TT - Trinidad e Tobago 3
AE - Emirati Arabi Uniti 2
BS - Bahamas 2
CL - Cile 2
ET - Etiopia 2
IR - Iran 2
PE - Perù 2
PY - Paraguay 2
SK - Slovacchia (Repubblica Slovacca) 2
UG - Uganda 2
UZ - Uzbekistan 2
ZA - Sudafrica 2
AL - Albania 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
CZ - Repubblica Ceca 1
EE - Estonia 1
GE - Georgia 1
GT - Guatemala 1
HU - Ungheria 1
ID - Indonesia 1
JM - Giamaica 1
KE - Kenya 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LT - Lituania 1
MA - Marocco 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
SR - Suriname 1
TW - Taiwan 1
Totale 2.420
Salva come PNG Salva come JPEG
Città #
Singapore 158
Ashburn 138
San Jose 88
Hong Kong 85
Fairfield 60
Beijing 52
Council Bluffs 52
The Dalles 38
New York 34
Los Angeles 33
Helsinki 30
Munich 28
Chandler 26
Houston 24
Princeton 24
Jacksonville 23
Cambridge 22
Dallas 22
Ho Chi Minh City 21
Seattle 21
Woodbridge 21
Santa Clara 17
Wilmington 17
Lauterbourg 16
Dublin 14
Hanoi 14
Milan 14
Sydney 14
Ann Arbor 13
Istanbul 12
Buffalo 11
Columbus 11
Rome 11
Turku 11
Orem 10
San Francisco 9
Montreal 8
Nuremberg 8
Phoenix 8
São Paulo 8
Athens 7
Brooklyn 7
Stockholm 7
Bergamo 6
Cairo 6
Chicago 6
North Bergen 6
Redondo Beach 6
San José 6
Shanghai 6
Amsterdam 5
Baghdad 5
Brescia 5
Melbourne 5
Mexico City 5
Rho 5
San Diego 5
San Salvador 5
Adelaide 4
Bosio 4
Brasília 4
Changsha 4
Denver 4
Des Moines 4
Dosso 4
Frankfurt am Main 4
Louisville 4
Moscow 4
Porto Alegre 4
Rawalpindi 4
Tokyo 4
Toronto 4
Amman 3
Atlanta 3
Catania 3
Curitiba 3
Dhaka 3
Duncan 3
Falkenstein 3
Gothenburg 3
London 3
Lucknow 3
Redwood City 3
Shenyang 3
Skopje 3
Toledo 3
Abu Dhabi 2
Addis Ababa 2
Bagheria 2
Baltimore 2
Bangkok 2
Bauru 2
Bengaluru 2
Billings 2
Biên Hòa 2
Boston 2
Bratislava 2
Buenos Aires 2
Caracas 2
Carolina 2
Totale 1.455
Salva come PNG Salva come JPEG
Nome #
COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study 227
DEVELOPMENT OF NEW PERSONALIZED DIAGNOSTIC AND THERAPEUTIC STRATEGIES IN GIANT CELL ARTERITIS: IDENTIFICATION OF NEW MARKERS FOR DISEASE SUBSETS AND PREDICTORS OF THERAPEUTIC RESPONSE 203
Effector T-cells are expanded in systemic lupus erythematosus patients with high disease activity and damage indexes 192
Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab 180
Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy. 159
Circulating follicular helper T cells (CD4+CXCR5+ICOS+) decrease in patients with rheumatoid arthritis treated with abatacept 149
Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients 149
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting 129
Pregnancy in antiphospholipid syndrome: what should a rheumatologist know? 116
CXCL-13 serum levels in patients with rheumatoid arthritis treated with abatacept 112
Retinal microvascular alterations in patients with active rheumatoid arthritis without cardiovascular risk factors: the potential effects of T cell co-stimulation blockade 105
Can we use NOACS in APS? 104
Retinal microvascular alterations in patients with active rheumatoid arthritis without cardiovascular risk factors: the potential effects of T cell co-stimulation blockade 98
Novel Therapies in Takayasu Arteritis. 94
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study-Joint and Skin (BeRLiSS-JS) 89
Novel Targets for Drug Use in Eosinophilic Granulomatosis With Polyangiitis 89
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort 88
Tapering belimumab in patients with systemic lupus erythematosus: a single-centre experience 79
The use of tumor necrosis factor inhibitors during high-risk pregnancies in antiphospholipid syndrome: a clinical report of a patient with concomitant Takayasu arteritis and case-based review 51
Giant cell arteritis in clinical practice: beyond GiACTA 32
Totale 2.445
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.105
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.105
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202287 0 0 0 0 4 4 5 10 6 14 20 24
2022/202383 14 1 3 3 9 26 0 8 10 0 6 3
2023/2024148 12 3 20 13 5 27 2 16 31 0 5 14
2024/2025493 7 13 8 48 27 36 45 22 28 65 123 71
2025/2026932 87 117 67 134 99 61 129 39 73 75 32 19
2026/2027347 45 47 87 147 21 0 0 0 0 0 0 0
Totale 2.445